
Ampersand Biomedicines: Innovating disease-targeted programming therapeutics via our AND™ Platform.
Founded by Flagship Pioneering, Ampersand Biomedicines is dedicated to revolutionizing drug development through its Address, Navigate, Design (AND)™ Platform. The company's core mission is to create novel programming therapeutics that act precisely at the site of disease, enhancing efficacy while maintaining safety and tolerability. Ampersand focuses on developing these targeted therapies to overcome the traditional challenges of affecting healthy tissues or cells, aiming to significantly improve patient outcomes.
Notable affiliated individuals include the team at Flagship Pioneering, a well-regarded venture capital firm known for incubating transformative biotech companies. Ampersand Biomedicines has achieved significant milestones in its early stages, particularly in advancing its AND™ Platform. The company's innovative approach has the potential to make a substantial impact on the biomedicine field by offering more precise and safer treatment options for various diseases.

ProFound Therapeutics
profoundtx.com

Alltrna
alltrna.com

Generate Biomedicines

Montai Health
montai.com

ABio-X
abio-x.com

Amber Bio
amber.bio

Amplifica
amplificabio.com

Surf Bio
surf.bio

Rectify Pharmaceuticals
rectifypharma.com

Endpoint Health
endpointhealth.com

Ampel Biosolutions

Cambrian BioPharma
cambrianbio.com

EpiBiologics
epibiologics.com

Amplicore

AltPep
altpep.com
Companies similar to Ampersand Biomedicines include ProFound Therapeutics, Alltrna, Generate Biomedicines and Montai Health.
Ampersand Biomedicines was founded in 2020.
Ampersand Biomedicines' headquarters is located in Boston, MA, US.
Ampersand Biomedicines' most recent funding round was for $50M (USD) in March 2023.
As of Mar 7, 2023, Ampersand Biomedicines has raised a total of $50M (USD).
Ampersand Biomedicines has 30 employees as of Feb 4, 2024.